

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **December 24, 2014**

---

**FATE THERAPEUTICS, INC.**

(Exact name of registrant as specified in its charter)

---

**Delaware**  
{State or other jurisdiction of  
incorporation)

**001-36076**  
(Commission File Number)

**65-1311552**  
(I.R.S. Employer Identification  
No.)

**3535 General Atomics Court, Suite 200  
San Diego, CA 92121**  
(Address of principal executive offices, including zip code)

**(858) 875-1800**  
(Registrant's telephone number, including area code)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

**Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.**

On December 24, 2014, Fate Therapeutics, Inc. (the “Company”) drew down an additional term loan in the principal amount of \$10.0 million (the “Term B Loan”) under its Amended and Restated Loan and Security Agreement, dated July 30, 2014, with Silicon Valley Bank (the “Loan Agreement”). The Term B Loan will mature on June 1, 2018 and bears interest at a fixed annual rate of 7.07%. The Term B Loan will be used to fund the Company’s research and development programs and for working capital purposes.

Additional details of the terms of the Loan Agreement were previously disclosed in a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on August 5, 2014, including Exhibits 10.1 and 10.2 thereto, and are incorporated herein by reference.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 30, 2014

**Fate Therapeutics, Inc.**

By: /s/ J. Scott Wolchko  
J. Scott Wolchko  
Chief Financial Officer and Chief Operating Officer